Exiqon this week announced it was offering BRAF mutation analysis through its CLIA laboratory in California.
UK-based DxS previously announced it was offering its TheraScreen KRAS Test and BRAF test in the US through Exiqon.
"BRAF testing is important because it can identify the subset of colorectal cancer patients who do not have a mutated KRAS gene yet still do not respond to anti-EGFR therapy," Exiqon said in a statement.
According to published studies, BRAF testing can help guide anti-EGFR treatment, with such drugs as cetuximab and panitumumab, for advance colorectal cancer patients.
Non-responsiveness in this subset of patients may have V600E mutation in the BRAF gene. "Testing patients for both KRAS and BRAF provides a more complete analysis of the patient's tumor when evaluating candidates for anti-EGFR therapy," the company said.